Jaypirca

(Pirtobrutinib)

ApprovedSmall molecule

Pirtobrutinib is used to treat certain types of blood cancers, specifically chronic lymphocytic leukemia and small lymphocytic lymphoma. It works by blocking a protein that helps cancer cells survive and grow.[2] Jaypirca is currently approved and in use across 28 indications[4].[1]

Jaypirca is one of 371 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Approved.

Indications

Total Trials

Active Trials

370

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Non-Small Cell Lung CancerApproved

PirtobrutinibNot yet recruiting

Renal InsufficiencyApproved

Waldenstrom MacroglobulinemiaActive, not recruiting

Hepatic FailureApproved

Non-Hodgkins LymphomaActive, not recruiting

Chronic Lymphocytic LeukemiaRecruiting

Immune Thrombocytopenia (ITP)Recruiting

Blood CancerRecruiting

Mantle Cell Lymphoma (MCL)Not yet recruiting

Non-Small Cell Lung CancerApproved

Approved

PirtobrutinibPhase 2

Not yet recruiting

Renal InsufficiencyApproved

Approved

Waldenstrom MacroglobulinemiaApproved

Active, not recruiting

Hepatic FailureApproved

Approved

Non-Hodgkins LymphomaApproved

Active, not recruiting

Chronic Lymphocytic LeukemiaApproved

Recruiting

Immune Thrombocytopenia (ITP)Preclinical

Recruiting

Blood CancerPhase 2

Recruiting

Mantle Cell Lymphoma (MCL)Phase 2

Not yet recruiting

Showing 10 of 28 indications

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Jaypirca

Eli Lilly

Approved

64 2

Tepmetko

EMD Serono

Phase 3

5 3

Fluorine F 18 Ara-G

AstraZeneca

Phase 3

1 4

Neladalkib (NVL-655)

NNuvalent Inc.

Phase 3

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Treatment

NCT06466122

Q1 2027

Phase 2Recruiting

Mantle Cell Lymphoma

NCT06263491

Q2 2027

Phase 2Recruiting

Mantle Cell Lymphoma

NCT05529069

Phase 3Active, not recruiting

Chronic Lymphocytic Leukemia

NCT04666038

Q3 2027

Phase 2Not yet recruiting

Diffuse Large B-Cell Lymphoma

NCT07122609

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia12 trials

Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting·MMayo Clinic·Phase 2·NCT05677919·72 enrolled

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05536349·60 enrolled

A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 2·NCT06839872

Show 9 more trials

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04666038·238 enrolled

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

Recruiting·IInhye Ahn·Phase 2·NCT06333262·60 enrolled

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05023980·309 enrolled

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recruiting·BBeOne Medicines·Phase 3·NCT06973187·500 enrolled

Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-20020 With BTKi Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting· Eli Lilly logo

Eli Lilly·Approved·NCT07218341·150 enrolled

Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib

Recruiting·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT06812715·40 enrolled

A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314)

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT05254743·737 enrolled

A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects

Recruiting·NNewave Pharmaceutical Inc·Phase 3·NCT07342478·306 enrolled

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06967610·40 enrolled

Mantle Cell Lymphoma8 trials

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04662255·500 enrolled

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Recruiting·AAustralasian Leukaemia and Lymphoma Group·Phase 2·NCT05833763·42 enrolled

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

Not yet recruiting·FFondazione Italiana Linfomi - ETS·Phase 2·NCT07207785·56 enrolled

Show 5 more trials

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

Recruiting·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT07285590·50 enrolled

Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06263491·50 enrolled

Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05529069·30 enrolled

A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT06252675·30 enrolled

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06522386·50 enrolled

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma5 trials

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05317936·3 enrolled

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT06588478·249 enrolled

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04965493·600 enrolled

Show 2 more trials

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Recruiting· Eli Lilly logo

Eli Lilly·Phase 4·NCT06876662·279 enrolled

A Phase 2 Trial of Single-Agent Pirtobrutinib for Elderly Patients With CLL

Recruiting·JJennifer Woyach·Phase 2·NCT07685717·50 enrolled

ART4 trials

A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06180980·20 enrolled

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06215521·31 enrolled

A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06258174·28 enrolled

Show 1 more trial

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06165146·16 enrolled

Interaction3 trials

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05176314·32 enrolled

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06194214·16 enrolled

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06180967·15 enrolled

29 more indications

Function2 trials

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06190691·36 enrolled

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06190678·16 enrolled

Treatment2 trials

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT07255963·29 enrolled

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

Recruiting·KKerry Rogers·Phase 2·NCT06466122·30 enrolled

DLBCL - Diffuse Large B Cell Lymphoma2 trials

A Prospective, Multicenter Clinical Study of Pirtobrutinib Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Newly Diagnosed Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL)

Not yet recruiting·CChangzhou No.2 People's Hospital·Phase 2·NCT07744724·48 enrolled

A Prospective, Multicenter Clinical Study of Pirtobrutinib Combined With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) for the Treatment of Previously Untreated Non-GCB DLBCL

Not yet recruiting·CChangzhou No.2 People's Hospital·Phase 2·NCT07744737·34 enrolled

Lymphoma1 trial

Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)

Recruiting·UUniversity of Utah·Phase 2·NCT06390956·23 enrolled

Adult1 trial

A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06181006·24 enrolled

Lymphoplasmacytic Lymphoma1 trial

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07231952·40 enrolled

Multiple Sclerosis1 trial

A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis

Withdrawn· Eli Lilly logo

Eli Lilly·Phase 2·NCT06104683

Blood Cancer1 trial

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07162181·13 enrolled

Macroglobulinemia1 trial

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Recruiting·—·Phase 2·NCT05734495·42 enrolled

Methotrexate1 trial

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Recruiting·TTongji Hospital·Phase 2·NCT07350850·110 enrolled

CLL/SLL1 trial

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT03740529·803 enrolled

MRD1 trial

Mosunetuzumab for CLL MRD Clearance

Recruiting·IInhye Ahn·Phase 1/2·NCT07052695·40 enrolled

Follicular Lymphoma1 trial

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Recruiting·UUniversity of Washington·Phase 2·NCT06948786·22 enrolled

Richter Transformation1 trial

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

Not yet recruiting·SSWOG Cancer Research Network·Phase 3·NCT07220187·102 enrolled

Cancer1 trial

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Approved for marketing· Eli Lilly logo

Eli Lilly··NCT05172700

Oral1 trial

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06215430·16 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Not yet recruiting·RRuijin Hospital·Phase 2·NCT07122609·22 enrolled

Richter's Transformation1 trial

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

Recruiting·CChristine Ryan·Phase 2·NCT06043674·70 enrolled

Randomized1 trial

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06553872·60 enrolled

Pirtobrutinib1 trial

Efficacy and Safety of Methotrexate (MTX) Combined With Chemoimmunotherapy Plus Pirtobrutinib in Patients With Systemic Diffuse Large B-Cell Lymphoma (DLBCL) and Central Nervous System Involvement

Not yet recruiting·PPengpeng Xu·Phase 2·NCT07812493·24 enrolled

Relapsed/Refractory Chronic Lymphocytic Leukemia1 trial

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Active, not recruiting· Genmab logo

Genmab·Preclinical·NCT04623541·194 enrolled

B-cell Lymphoma1 trial

A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Recruiting·NNurix Therapeutics, Inc.·Phase 3·NCT07516093·620 enrolled

Refractory Mantle Cell Lymphoma (MCL)1 trial

A Randomized, Multicenter, Open-label, Phase 3 Study to Compare ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL)

Not yet recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT07784101·280 enrolled

Chronic Lymphocytic Leukemia (CLL)1 trial

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

Recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT07428707·30 enrolled

Non-Hodgkin Lymphoma1 trial

Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Recruiting·MMedical College of Wisconsin·Phase 1·NCT05990465·12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05024045·27 enrolled

Mantle Cell Lymphoma (MCL)1 trial

A Prospective Phase 2 Study of Lisaftoclax Plus Pirtobrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma After Failure of BTK-Targeted Therapy

Not yet recruiting·HHenan Cancer Hospital·Phase 2·NCT07684950·45 enrolled

Immune Thrombocytopenia (ITP)1 trial

A Phase 1/2, Dose-finding Study Investigating the Safety and Efficacy of Pirtobrutinib in Adults With Immune Thrombocytopenia

Recruiting· Eli Lilly logo

Eli Lilly·Preclinical·NCT06721013·68 enrolled

Unspecified1 trial

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Recruiting· Eli Lilly logo

Eli Lilly·Phase 4·NCT06876649·787 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 27, 2023

JAYPIRCA

NDA NDA216059

Jan 27, 2023

JAYPIRCA

NDA NDA216059

Jun 4, 2024

JAYPIRCA

NDA NDA216059

Dec 2, 2025

JAYPIRCA

NDA NDA216059

Sources

References

[1]
ClinicalTrials.gov — 64 trial records for Pirtobrutinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jaypirca drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Pirtobrutinib compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Pirtobrutinib. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216059). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Jaypirca. U.S. Food & Drug Administration.
[7]
PubMed — 1 publication indexed for Pirtobrutinib. U.S. National Library of Medicine.
[8]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: BTK Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Eli Lilly

Patent Landscape[6]

Patent Cliff

Dec 16, 2036

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12220401Dec 16, 2036

10695323Dec 16, 2036

10464905Dec 16, 2036

10918622Dec 16, 2036

10342780Dec 16, 2036

2 more patents

12268666Jul 29, 2039

12109193Sep 14, 2041

Key Publications[7]

Pirtobrutinib in Relapsed/Refractory Mantle Cell Lymphoma: BRUIN

N Engl J MedNov 16, 2023DOI: 10.1056/NEJMoa2311400

Jaypirca

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Chronic Lymphocytic Leukemia12 trials

Mantle Cell Lymphoma8 trials

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma5 trials

ART4 trials

Interaction3 trials

Function2 trials

Treatment2 trials

DLBCL - Diffuse Large B Cell Lymphoma2 trials

Lymphoma1 trial

Adult1 trial

Lymphoplasmacytic Lymphoma1 trial

Multiple Sclerosis1 trial

Blood Cancer1 trial

Macroglobulinemia1 trial

Methotrexate1 trial

CLL/SLL1 trial

MRD1 trial

Follicular Lymphoma1 trial

Richter Transformation1 trial

Cancer1 trial

Oral1 trial

Diffuse Large B-Cell Lymphoma1 trial

Richter's Transformation1 trial

Randomized1 trial

Pirtobrutinib1 trial

Relapsed/Refractory Chronic Lymphocytic Leukemia1 trial

B-cell Lymphoma1 trial

Refractory Mantle Cell Lymphoma (MCL)1 trial

Chronic Lymphocytic Leukemia (CLL)1 trial

Non-Hodgkin Lymphoma1 trial

Leukemia, Lymphocytic, Chronic, B-Cell1 trial

Mantle Cell Lymphoma (MCL)1 trial

Immune Thrombocytopenia (ITP)1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Key Publications[7]

Related News